Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)

v3.20.2
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-In Capital [Member]
Subscription Receivable [Member]
Common Stock Dividend Payable [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2018 $ 552 $ 19,124,600 $ (1,800,000)   $ (7,624,134) $ 9,701,018
Balance, shares at Dec. 31, 2018 5,525,009          
Stock-based compensation 58,559   58,559
Payments made directly by investor for clinical trial costs 115,000   115,000
Net loss   (750,832) (750,832)
Balance at Mar. 31, 2019 $ 552 19,183,159 (1,685,000)   (8,374,966) 9,123,745
Balance, shares at Mar. 31, 2019 5,525,009          
Balance at Dec. 31, 2018 $ 552 19,124,600 (1,800,000)   (7,624,134) 9,701,018
Balance, shares at Dec. 31, 2018 5,525,009          
Net loss           (1,719,910)
Balance at Jun. 30, 2019 $ 552 19,249,635 (1,404,073)   (9,344,044) 8,502,070
Balance, shares at Jun. 30, 2019 5,525,009          
Balance at Mar. 31, 2019 $ 552 19,183,159 (1,685,000)   (8,374,966) 9,123,745
Balance, shares at Mar. 31, 2019 5,525,009          
Stock-based compensation 66,476   66,476
Payments made directly by investor for clinical trial costs 280,927   280,927
Net loss   (969,078) (969,078)
Balance at Jun. 30, 2019 $ 552 19,249,635 $ (1,404,073)   (9,344,044) 8,502,070
Balance, shares at Jun. 30, 2019 5,525,009          
Balance at Dec. 31, 2019 $ 549 18,994,008   $ 3 (10,982,010) 8,012,550
Balance, shares at Dec. 31, 2019 5,486,476          
Stock-based compensation 98,663   98,663
Transaction costs related to anticipated 2020 offering (2,806)   (2,806)
Net loss   (874,336) (874,336)
Balance at Mar. 31, 2020 $ 549 19,089,865   3 (11,856,346) 7,234,071
Balance, shares at Mar. 31, 2020 5,486,476          
Balance at Dec. 31, 2019 $ 549 18,994,008   3 (10,982,010) 8,012,550
Balance, shares at Dec. 31, 2019 5,486,476          
Net loss           (1,607,750)
Balance at Jun. 30, 2020 $ 552 19,182,228   (12,589,760) 6,593,020
Balance, shares at Jun. 30, 2020 5,515,447          
Balance at Mar. 31, 2020 $ 549 19,089,865   3 (11,856,346) 7,234,071
Balance, shares at Mar. 31, 2020 5,486,476          
Stock-based compensation 93,869   93,869
Transaction costs related to anticipated 2020 offering (1,506)   (1,506)
Stock dividend distributed due to full-ratchet anti-dilution adjustment $ 3   (3)
Stock dividend distributed due to full-ratchet anti-dilution adjustment, shares 28,971          
Net loss   (733,414) (733,414)
Balance at Jun. 30, 2020 $ 552 $ 19,182,228   $ (12,589,760) $ 6,593,020
Balance, shares at Jun. 30, 2020 5,515,447